ELI LILLY AND COMPANY and Immunocore Limited entered into a co-discovery and co-development collaboration to research and develop novel T cell-based cancer therapies.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
